Erratum: In Vitro and in Vivo Anti-Schistosomal Activity of the Alkylphospholipid Analog Edelfosine (PLoS ONE (2014) 9:10 (e109431) DOI: 10.1371/journal.pone.0109431);In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Yepes, Edward ^a   Varela M, Rubén E ^a   López Abán, Julio ^a   Dakir, E L Habib ^a   Mollinedo, Faustino ^a   Muro, Antonio ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLPHOSPHOLIPID; ANTISCHISTOSOMAL AGENT; EDELFOSINE; ERUCYLPHOSPHOCHOLINE; MILTEFOSINE; PERIFOSINE; PHOSPHOLIPID DERIVATIVE; PRAZIQUANTEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ETHER PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISCHISTOSOMAL ACTIVITY; APOPTOSIS; ARTICLE; CELL MEMBRANE PERMEABILITY; CERCARIA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG POTENCY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTEGUMENT; MOUSE; MTT ASSAY; NICK END LABELING; NONHUMAN; PARASITE LOAD; PARASITE VIABILITY; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPARASITIC AGENTS; APOPTOSIS; FEMALE; MICE; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 84907835020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123149     Document Type: Erratum

References (74)

1. Muro A, Pérez del Villar L (2012) Schistosoma and Schistosomiasis. In: Liu D, editor. Molecular Detection of Human Parasitic Pathogens: CRC Press. pp.441-454.
2. Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, et al. (2002) Schistosomiasis. N Engl J Med 346: 1212-1220.
3. Pearce EJ, MacDonald AS (2002) The immunobiology of schistosomiasis. Nat Rev Immunol 2: 499-511.
4. Hams E, Aviello G, Fallon PG (2013) The schistosoma granuloma: friend or foe? Front Immunol 4: 89.
5. WHO: Schistosomiasis. Available: http://www.who.int/schistosomiasis/en/. Accessed 24 April, 2014.
6. WHO: Schistosomiasis, Fact sheet Nu 115, Update February 2014. Available: http://www.who.int/mediacentre/factsheets/fs115/en/. Accessed 24 April, 2014.
7. King CH (2010) Parasites and poverty: the case of schistosomiasis. Acta Trop 113: 95-104.
8. Rokni MB (2012) Schistosomiasis. In: Rokni MB, editor. Schistosomiasis: InTech. pp.310.
9. Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19: 509-515.
10. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659-667.
11. Pica-Mattoccia L, Cioli D (2012) Praziquantel: Too Good to be Replaced? Parasitic Helminths: Wiley-VCH Verlag GmbH & Co. KGaA. C.R. . Caffrey, ed. pp.309-321.
12. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet 368: 1106-1118.
13. Perez del Villar L, Burguillo FJ, Lopez-Aban J, Muro A (2012) Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 7: e45867.
14. Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J (2013) Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev 2: CD000528.
15. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS (2011) Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasit Vectors 4: 201.
16. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, et al. (2009) Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3: e504.
17. Danker K, Reutter W, Semini G (2010) Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol 160: 36-47.
18. van Blitterswijk WJ, Verheij M (2013) Anticancer mechanisms and clinical application of alkylphospholipids. Biochim Biophys Acta 1831: 663-674.
19. Gajate C, Mollinedo F (2002) Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 3: 491-525.
20. 3(Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 57: 1320-1328.
21. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, et al. (2010) In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 16: 2046-2054.
22. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, et al. (2010) Lipid raft-targeted therapy in multiple myeloma. Oncogene 29: 3748-3757.
23. Gajate C, Mollinedo F (2001) The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98: 3860-3863.
24. Gajate C, Mollinedo F (2007) Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109: 711-719.
25. Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, et al. (2004) Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 200: 353-365.
26. Varela MR, Villa-Pulgarin JA, Yepes E, Muller I, Modolell M, et al. (2012) In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. PLoS Negl Trop Dis 6: e1612.
27. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M (2006) Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100 Suppl 1: S26-33.
28. Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM (2011) Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol 41: 235-242.
29. Cota GF, Gomes LI, Pinto BF, Santos-Oliveira JR, Da-Cruz AM, et al. (2012) Dyarrheal Syndrome in a Patient Co-Infected with Leishmania infantum and Schistosoma mansoni. Case Rep Med 2012: 240512.
30. Abruzzi A, Fried B (2011) Coinfection of Schistosoma (Trematoda) with bacteria, protozoa and helminths. Adv Parasitol 77: 1-85.
31. Lewis F (2001) Schistosomiasis. Curr Protoc Immunol Chapter 19: Unit 19 11.
32. Mann VH, Morales ME, Rinaldi G, Brindley PJ (2010) Culture for genetic manipulation of developmental stages of Schistosoma mansoni. Parasitology 137: 451-462.
33. Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, et al. (2007) In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 51: 1440-1445.
34. Manneck T, Haggenmuller Y, Keiser J (2010) Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 137: 85-98.
35. Peak E, Hoffmann KF (2011) Cross-disciplinary approaches for measuring parasitic helminth viability and phenotype. An Acad Bras Cienc 83: 649-662.
36. Nare B, Smith JM, Prichard RK (1991) Differential effects of oltipraz and its oxy-analogue on the viability of Schistosoma mansoni and the activity of glutathione S-transferase. Biochem Pharmacol 42: 1287-1292.
37. Mollinedo F, Fernandez M, Hornillos V, Delgado J, Amat-Guerri F, et al. (2011) Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis 2: e158.
38. Gajate C, Matos-da-Silva M, Dakir el H, Fonteriz RI, Alvarez J, et al. (2012) Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene 31: 2627-2639.
39. Galanti SE, Huang SC, Pearce EJ (2012) Cell death and reproductive regression in female Schistosoma mansoni. PLoS Negl Trop Dis 6: e1509.
40. Zhang CW, Xiao SH, Utzinger J, Chollet J, Keiser J, et al. (2009) Histopathological changes in adult Schistosoma japonicum harbored in mice treated with a single dose of mefloquine. Parasitol Res 104: 1407-1416.
41. Cheever AW (1970) Relative resistance of the eggs of human schistosomes to digestion in potassium hydroxide. Bull World Health Organ 43: 601-603.
42. Estella-Hermoso de Mendoza A, Campanero MA, de la Iglesia-Vicente J, Gajate C, Mollinedo F, et al. (2009) Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res 15: 858-864.
43. Jurberg AD, Goncalves T, Costa TA, de Mattos AC, Pascarelli BM, et al. (2009) The embryonic development of Schistosoma mansoni eggs: proposal for a new staging system. Dev Genes Evol 219: 219-234.
44. Mollinedo F (2007) Antitumour ether lipids: proapoptotic agents with multiple therapeutic indications. Expert Opinion on Therapeutic Patents 17: 385-405.
45. Bertao HG, da Silva RA, Padilha RJ, de Azevedo Albuquerque MC, Radis-Baptista G (2012) Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res 110: 2465-2473.
46. Marr JJ, Nilsen TW, Komuniecki R (2003) Molecular medical parasitology. Amsterdam; Boston: Academic Press. xii, 488 p.
47. Jones MK, Gobert GN, Zhang L, Sunderland P, McManus DP (2004) The cytoskeleton and motor proteins of human schistosomes and their roles in surface maintenance and host-parasite interactions. Bioessays 26: 752-765.
48. Skelly PJ (2005) The surface of schistosomes within the vertebrate host. In: Secor WE, Colley, Daniel G., editor. Schistosomiasis. pp.82-100.
49. Wilson RA (2012) The cell biology of schistosomes: a window on the evolution of the early metazoa. Protoplasma 249: 503-518.
50. McLaren DJ, Hockley DJ (1977) Blood flukes have a double outer membrane. Nature 269: 147-149.
51. Ruppel A, McLaren DJ (1986) Schistosoma mansoni: surface membrane stability in vitro and in vivo. Exp Parasitol 62: 223-236.
52. Van Hellemond JJ, Retra K, Brouwers JF, van Balkom BW, Yazdanbakhsh M, et al. (2006) Functions of the tegument of schistosomes: clues from the proteome and lipidome. Int J Parasitol 36: 691-699.
53. Faghiri Z, Skelly PJ (2009) The role of tegumental aquaporin from the human parasitic worm, Schistosoma mansoni, in osmoregulation and drug uptake. FASEB J 23: 2780-2789.
54. Pereira AS, Padilha RJ, Lima-Filho JL, Chaves ME (2011) Scanning electron microscopy of the human low-density lipoprotein interaction with the tegument of Schistosoma mansoni. Parasitol Res 109: 1395-1402.
55. Shaw MK, Erasmus DA (1983) Schistosoma mansoni: dose-related tegumental surface changes after in vivo treatment with praziquantel. Z Parasitenkd 69: 643-653.
56. Fallon PG, Fookes RE, Wharton GA (1996) Temporal differences in praziquantel- and oxamniquine-induced tegumental damage to adult Schistosoma mansoni: implications for drug-antibody synergy. Parasitology 112 (Pt 1): 47-58.
57. Xiao S, Binggui S, Chollet J, Tanner M (2000) Tegumental changes in 21-dayold Schistosoma mansoni harboured in mice treated with artemether. Acta Trop 75: 341-348.
58. Xiao SH, Xue J, Shen B (2010) Transmission electron microscopic observation on ultrastructural alterations in Schistosoma japonicum caused by mefloquine. Parasitol Res 106: 1179-1187.
59. Soliman MF, Ibrahim MM (2005) Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study. Acta Trop 93: 1-9.
60. Neves JK, de Lima Mdo C, Pereira VR, de Melo CM, Peixoto CA, et al. (2011) Antischistosomal action of thioxo-imidazolidine compounds: an ultrastructural and cytotoxicity study. Exp Parasitol 128: 82-90.
61. Eissa MM, El Bardicy S, Tadros M (2011) Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy. Parasit Vectors 4: 73.
62. Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ (2012) Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67: 2576-2597.
63. Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, et al. (2009) Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther 329: 439-449.
64. Gonnert R, Andrews P (1977) Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd 52: 129-150.
65. Cioli D, Pica-Mattoccia L (2003) Praziquantel. Parasitol Res 90 Supp 1: S3-9.
66. King CH, Muchiri EM, Ouma JH (2000) Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis 6: 585-594.
67. Fenwick A, Webster JP (2006) Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 19: 577-582.
68. Norton AJ, Gower CM, Lamberton PH, Webster BL, Lwambo NJ, et al. (2010) Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am J Trop Med Hyg 83: 951-957.
69. Kunz W (2001) Schistosome male-female interaction: induction of germ-cell differentiation. Trends Parasitol 17: 227-231.
70. Utzinger J, Chollet J, You J, Mei J, Tanner M, et al. (2001) Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals. Acta Trop 80: 9-18.
71. Keiser J, Manneck T, Vargas M (2011) Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother 66: 1791-1797.
72. O'Neal SE, Guimaraes LH, Machado PR, Alcantara L, Morgan DJ, et al. (2007) Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis 195: 142-148.
73. Hassan MF, Zhang Y, Engwerda CR, Kaye PM, Sharp H, et al. (2006) The Schistosoma mansoni hepatic egg granuloma provides a favorable microenvironment for sustained growth of Leishmania donovani. Am J Pathol 169: 943-953.
74. La Flamme AC, Scott P, Pearce EJ (2002) Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing by macrophages. Parasite Immunol 24: 339-345.